Want to see HK:0775 full AI Analyst Report?
CK Life Sciences International (Holdings), Inc. (0775) Ratios
CK Life Sciences International (Holdings), Inc. Ratios
HK:0775's free cash flow for Q2 2026 was $-50.00M. For the 2026 fiscal year, HK:0775's free cash flow was increased by $0.00 and operating cash flow was $-50.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.87 | 1.28 | 1.42 | 0.77 | 1.53 |
| Quick Ratio | 0.51 | 0.78 | 0.85 | 0.45 | 0.92 |
| Cash Ratio | 0.17 | 0.24 | 0.32 | 0.17 | 0.43 |
| Solvency Ratio | -0.01 | -0.00 | 0.04 | 0.03 | 0.04 |
| Operating Cash Flow Ratio | -0.01 | 0.15 | 0.24 | 0.09 | 0.20 |
| Short-Term Operating Cash Flow Coverage | -0.01 | 0.28 | 0.45 | 0.12 | 0.35 |
| Net Current Asset Value | $ -4.98B | $ -4.31B | $ -4.07B | $ -3.99B | $ -4.06B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.56 | 0.57 | 0.53 | 0.53 | 0.53 |
| Debt-to-Equity Ratio | 1.75 | 1.74 | 1.42 | 1.43 | 1.38 |
| Debt-to-Capital Ratio | 0.64 | 0.63 | 0.59 | 0.59 | 0.58 |
| Long-Term Debt-to-Capital Ratio | 0.49 | 0.54 | 0.50 | 0.36 | 0.49 |
| Financial Leverage Ratio | 3.13 | 3.07 | 2.68 | 2.71 | 2.60 |
| Debt Service Coverage Ratio | -0.08 | 0.19 | 0.39 | 0.12 | 0.28 |
| Interest Coverage Ratio | -0.51 | 2.32 | 0.69 | 1.35 | 2.39 |
| Debt to Market Cap | 0.76 | 1.39 | 0.91 | 0.72 | 0.79 |
| Interest Debt Per Share | 0.72 | 0.67 | 0.65 | 0.64 | 0.66 |
| Net Debt to EBITDA | -121.79 | 16.44 | 8.43 | 11.19 | 11.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 14.52% | 30.65% | 30.76% | 30.82% | 30.17% |
| EBIT Margin | -2.50% | 4.45% | 7.35% | 6.97% | 6.20% |
| EBITDA Margin | -0.91% | 6.11% | 11.74% | 8.90% | 8.31% |
| Operating Profit Margin | -2.50% | 14.18% | 4.21% | 4.16% | 4.33% |
| Pretax Profit Margin | -0.33% | -1.66% | 1.29% | 3.88% | 4.41% |
| Net Profit Margin | -3.48% | -2.29% | 0.32% | 2.50% | 3.01% |
| Continuous Operations Profit Margin | -3.48% | -2.29% | 0.32% | 2.50% | 3.01% |
| Net Income Per EBT | 1046.29% | 138.34% | 25.15% | 64.41% | 68.34% |
| EBT Per EBIT | 13.31% | -11.68% | 30.64% | 93.33% | 101.95% |
| Return on Assets (ROA) | -1.59% | -1.17% | 0.15% | 1.17% | 1.39% |
| Return on Equity (ROE) | -4.99% | -3.60% | 0.41% | 3.17% | 3.61% |
| Return on Capital Employed (ROCE) | -1.62% | 9.24% | 2.45% | 3.05% | 2.42% |
| Return on Invested Capital (ROIC) | -1.25% | 7.97% | 0.54% | 1.37% | 1.46% |
| Return on Tangible Assets | -2.22% | -1.72% | 0.22% | 1.72% | 2.02% |
| Earnings Yield | -2.39% | -3.21% | 0.29% | 1.74% | 2.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.56 | 5.05 | 5.96 | 5.31 | 6.01 |
| Payables Turnover | 12.40 | 11.53 | 10.29 | 8.86 | 13.52 |
| Inventory Turnover | 3.76 | 3.31 | 3.06 | 2.84 | 3.01 |
| Fixed Asset Turnover | 1.99 | 2.15 | 1.94 | 2.03 | 1.95 |
| Asset Turnover | 0.46 | 0.51 | 0.47 | 0.47 | 0.46 |
| Working Capital Turnover Ratio | 56.83 | 7.16 | -233.66 | 67.39 | 3.11 |
| Cash Conversion Cycle | 133.27 | 150.87 | 145.11 | 156.03 | 155.08 |
| Days of Sales Outstanding | 65.60 | 72.23 | 61.28 | 68.73 | 60.76 |
| Days of Inventory Outstanding | 97.11 | 110.29 | 119.29 | 128.51 | 121.32 |
| Days of Payables Outstanding | 29.44 | 31.65 | 35.47 | 41.21 | 26.99 |
| Operating Cycle | 162.71 | 182.52 | 180.58 | 197.24 | 182.08 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | 0.04 | 0.05 | 0.04 | 0.04 |
| Free Cash Flow Per Share | -0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
| Dividend Paid and CapEx Coverage Ratio | -0.13 | 1.80 | 1.39 | 1.16 | 1.35 |
| Capital Expenditure Coverage Ratio | -0.13 | 1.80 | 1.76 | 1.68 | 1.95 |
| Operating Cash Flow Coverage Ratio | -0.00 | 0.06 | 0.09 | 0.06 | 0.07 |
| Operating Cash Flow to Sales Ratio | -0.01 | 0.06 | 0.10 | 0.07 | 0.08 |
| Free Cash Flow Yield | -3.52% | 3.98% | 3.73% | 1.93% | 2.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -42.27 | -31.14 | 345.44 | 57.54 | 43.69 |
| Price-to-Sales (P/S) Ratio | 1.46 | 0.71 | 1.12 | 1.44 | 1.32 |
| Price-to-Book (P/B) Ratio | 2.09 | 1.12 | 1.42 | 1.83 | 1.58 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.37 | 25.10 | 26.80 | 51.76 | 34.47 |
| Price-to-Operating Cash Flow Ratio | -240.48 | 11.15 | 11.59 | 20.88 | 16.79 |
| Price-to-Earnings Growth (PEG) Ratio | -0.90 | 0.04 | -3.98 | -3.04 | 1.46 |
| Enterprise Value Multiple | -281.27 | 28.13 | 17.97 | 27.36 | 27.68 |
| Enterprise Value | 13.90B | 9.49B | 11.23B | 12.85B | 12.43B |
| EV to EBITDA | -281.27 | 28.13 | 17.97 | 27.36 | 27.68 |
| EV to Sales | 2.57 | 1.72 | 2.11 | 2.44 | 2.30 |
| EV to Free Cash Flow | -50.04 | 60.42 | 50.49 | 87.58 | 60.27 |
| EV to Operating Cash Flow | -424.12 | 26.83 | 21.83 | 35.33 | 29.36 |
| Tangible Book Value Per Share | 0.05 | 0.01 | 0.06 | 0.06 | 0.09 |
| Shareholders’ Equity Per Share | 0.39 | 0.37 | 0.44 | 0.43 | 0.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -9.46 | -0.38 | 0.75 | 0.36 | 0.32 |
| Revenue Per Share | 0.56 | 0.57 | 0.55 | 0.55 | 0.56 |
| Net Income Per Share | -0.02 | -0.01 | 0.00 | 0.01 | 0.02 |
| Tax Burden | 10.46 | 1.38 | 0.25 | 0.64 | 0.68 |
| Interest Burden | 0.13 | -0.37 | 0.18 | 0.56 | 0.71 |
| Research & Development to Revenue | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 |
| SG&A to Revenue | 0.11 | 0.04 | 0.02 | 0.01 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.18 | -2.79 | 29.81 | 1.78 | 1.78 |
Currency in HKD
